Holen Sie sich die Stockscreener-App
0.4118
2.56%
-0.0108
Schlusskurs vom Vortag:
$0.4226
Offen:
$0.41
24-Stunden-Volumen:
174.95K
Relative Volume:
0.91
Marktkapitalisierung:
$634.75K
Einnahmen:
$743.00K
Nettoeinkommen (Verlust:
$-7.63M
KGV:
-0.1373
EPS:
-3
Netto-Cashflow:
-
1W Leistung:
-13.29%
1M Leistung:
-33.58%
6M Leistung:
-63.40%
1J Leistung:
-80.94%
1-Tages-Spanne:
$0.4065
$0.42
1-Wochen-Bereich:
$0.4065
$0.4814
52-Wochen-Spanne:
$0.4065
$2.50
Can-Fite Biopharma Ltd ADR Stock (CANF) Company Profile
Firmenname
Can-Fite Biopharma Ltd ADR
Sektor
Branche
Telefon
972 3 924 1114
Adresse
10 Bareket Street, Kiryat Matalon PO Box 7537, Petah-Tikva
Vergleichen Sie CANF mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CANF
Can-Fite Biopharma Ltd ADR
|
0.4118 | 7.22M | 743.00K | -7.63M | 0 | -3.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Can-Fite Biopharma Ltd ADR Stock (CANF) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2017-08-11 | Eingeleitet | Maxim Group | Buy |
| 2016-10-19 | Fortgesetzt | ROTH Capital | Buy |
| 2016-08-29 | Fortgesetzt | Rodman & Renshaw | Buy |
| 2015-11-30 | Bestätigt | H.C. Wainwright | Buy |
| 2015-03-31 | Bestätigt | H.C. Wainwright | Buy |
| 2015-03-30 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2014-12-29 | Bestätigt | ROTH Capital | Buy |
| 2014-11-18 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Can-Fite Biopharma Ltd ADR Aktie (CANF) Neueste Nachrichten
Will Can Fite Biopharma Ltd Sponsored ADR stock see insider accumulation2025 Technical Overview & Fast Entry High Yield Stock Tips - newser.com
Can Can Fite Biopharma Ltd Sponsored ADR stock deliver double digit returnsMarket Growth Summary & Short-Term Trading Opportunity Alerts - newser.com
How big funds are accumulating Can Fite Biopharma Ltd Sponsored ADR stockTrade Ideas & Weekly Top Gainers Trade List - newser.com
Why retail traders accumulate Can Fite Biopharma Ltd Sponsored ADR stockJuly 2025 Sector Moves & Fast Exit Strategy with Risk Control - newser.com
Will Can Fite Biopharma Ltd Sponsored ADR stock benefit from mergersMarket Sentiment Report & Real-Time Volume Spike Alerts - fcp.pa.gov.br
Why Can Fite Biopharma Ltd Sponsored ADR stock could rally stronglyJuly 2025 Technicals & Free Community Supported Trade Ideas - fcp.pa.gov.br
Why Can Fite Biopharma Ltd Sponsored ADR stock is a strong analyst pickQuarterly Profit Report & Free Technical Confirmation Trade Alerts - newser.com
Why Can Fite Biopharma Ltd Sponsored ADR stock is a strong buy callTake Profit & Verified Momentum Stock Ideas - newser.com
Will Can Fite Biopharma Ltd Sponsored ADR stock beat growth indexesJuly 2025 Big Picture & AI Enhanced Trading Alerts - newser.com
Why Can Fite Biopharma Ltd Sponsored ADR stock could outperform next yearGlobal Markets & Weekly Return Optimization Alerts - newser.com
Why pension funds invest in Can Fite Biopharma Ltd Sponsored ADR stockJuly 2025 Selloffs & Reliable Trade Execution Plans - newser.com
Why Can Fite Biopharma Ltd Sponsored ADR stock fits value portfolios2025 Bull vs Bear & Smart Allocation Stock Reports - newser.com
Is Can Fite Biopharma Ltd Sponsored ADR stock expanding market penetration2025 Historical Comparison & AI Powered Buy and Sell Recommendations - newser.com
Is Can Fite Biopharma Ltd Sponsored ADR stock a contrarian opportunityEarnings Miss & Real-Time Volume Triggers - newser.com
Finanzdaten der Can-Fite Biopharma Ltd ADR-Aktie (CANF)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.64%
0.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):